// App-Quantinova.ai

9052 : Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.

Researchers

Presenter

  • Paola Ulivi

Principal Investigators

  • Elisabetta Petracci

  • Elisa Chiadini

  • Claudio Dazzi

  • Laura Capelli

  • Alessandro Gamboni

  • Claudia Casanova

  • Maximilian Papi

  • Marita Mariotti

  • Nicoletta De Luigi

  • Marco Angelo Burgio

  • Vienna Ludovini

  • Chiara Bennati

  • Rita Chiari

  • Daniele Calistri

  • Lucio Crino

  • Dino Amadori

  • Angelo Delmonte

Medical Centers

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Diatech Pharmacogenetics, Jesi, Italy

  • Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Medical Oncology Unit, S.Maria delle Croci Hospital, Ravenna, Italy

  • Department of Oncology and Hematology, Degli Infermi Hospital, Faenza, Italy

  • Infermi Hospital, Rimini, Italy

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy

  • Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Tumor protein p53

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved